|
Synonyms: DYNE-101 | z-basivarsen
Compound class:
Nucleic acid
Comment: Zeleciment basivarsen (DYNE-101) is structurally a Fab-oligonucleotide conjugate in which the Fab binds the transferrin receptor (TFRC;) for targeted delivery of an antisense oligonucleotide (ASO) payload that binds nuclear DMPK RNA.
This entry provides information on the ASO as the component that mediates the agent's pharmacodynamic effect. The ASO is intended to reduce the acummulation of toxic RNA species (in the nucleus) that contain CTG trinucleotide repeat expansions in the 3′ UTR of the DMPK gene, which is the causitive genetic defect in myotonic dystrophy type 1 pathogenesis. n.b., the parental zeleciment Fab has been constructed with the rostudirsen ASO payload to promote functional dystrophin (DMD) synthesis. |
| No information available. |
Summary of Clinical Use ![]() |
| Zeleciment basivarsen (DYNE-101) was progressed as a clinical candidate for potential to traat myotonic dystrophy type 1. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT05481879 | Safety, Tolerability, Pharmacodynamic, Efficacy, and Pharmacokinetic Study of DYNE-101 in Participants With Myotonic Dystrophy Type 1 | Phase 1/Phase 2 Interventional | Dyne Therapeutics | ||
| NCT07486934 | Efficacy, Safety, and Tolerability of Zeleciment Basivarsen (DYNE-101) in Participants With Myotonic Dystrophy Type 1 | Phase 3 Interventional | Dyne Therapeutics | ||